Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Helene Hanaire-Broutin"'
Autor:
Bernard Zinman, V. Melki, Jackie Hochman, Robert J. Heine, Helene Hanaire-Broutin, Ravi Retnakaran, J. Hans DeVries
Publikováno v:
Diabetes Care. 27:2590-2596
OBJECTIVE—Rapid-acting insulin analogs (insulin lispro and insulin aspart) have emerged as the meal insulin of choice in both multiple daily insulin injection (MDII) therapy and continuous subcutaneous insulin infusion (CSII) for type 1 diabetes. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91b4c86e75ce4087fbcdd3411ab73688
https://doi.org/10.2337/diacare.27.11.2590
https://doi.org/10.2337/diacare.27.11.2590
Autor:
Pascale Abrams, Hanne Lang, David Russell-Jones, Philip Home, Birgitte Hylleberg, Helene Hanaire-Broutin, Paul Anthony Bartley, Eberhard Draeger, Jan-Evert Heeg, Mona Landin-Olsson
Publikováno v:
Diabetes Care. 27:1081-1087
OBJECTIVE—Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the limitations of conventional basal insulin formulations. Accordingly, insulin detemir has been compared with NPH insulin with respect to glycemic contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4644202251ee9ba941b5a6b92550585c
https://doi.org/10.2337/diacare.27.5.1081
https://doi.org/10.2337/diacare.27.5.1081
Autor:
Bruno Guerci, V. Lassmann-Vague, Nathalie Jeandidier, Helene Hanaire-Broutin, Christiane Broussolle, Eric Renard, M. J. Haardt
Publikováno v:
Diabetes Care. 18:388-392
OBJECTIVE To report the overall French experience, obtained through the collaboration of seven centers (EVADIAC [Evaluation dans le Diabète du Traitement par Implants Actifs] register), on the safety, feasibility, and efficacy of intraperitoneal ins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa576c6d71c27b7ea155e1b3976aca34
https://doi.org/10.2337/diacare.18.3.388
https://doi.org/10.2337/diacare.18.3.388
Autor:
Ravi, Retnakaran, Jackie, Hochman, J Hans, DeVries, Helene, Hanaire-Broutin, Robert J, Heine, Vincent, Melki, Bernard, Zinman
Publikováno v:
Diabetes care. 27(11)
Rapid-acting insulin analogs (insulin lispro and insulin aspart) have emerged as the meal insulin of choice in both multiple daily insulin injection (MDII) therapy and continuous subcutaneous insulin infusion (CSII) for type 1 diabetes. Thus, a compa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a229abbd794b9cf6b96c5ecd8aff7d0e
https://pubmed.ncbi.nlm.nih.gov/15983353
https://pubmed.ncbi.nlm.nih.gov/15983353
Publikováno v:
Diabetes care. 23(9)
OBJECTIVE: To compare the efficacy of 2 intensified insulin regimens, continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI), by using the short-acting insulin analog lispro in type 1 diabetic patients. RESEARCH DESIGN AN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb1672399aa6c95ab1c3289ef78596a
https://pubmed.ncbi.nlm.nih.gov/10977011
https://pubmed.ncbi.nlm.nih.gov/10977011
Autor:
P. Belicar, S Boivin, Eric Renard, Jacques Bringer, V. Melki, Laurent Meyer, Béatrice Augendre-Ferrante, V. Lassmann-Vague, Jean-Pierre Tauber, Helene Hanaire-Broutin, Bruno Guerci, Nathalie Jeandidier, Patrick Blin
Publikováno v:
Diabetes care. 21(6)
OBJECTIVE To compare the efficacy of the short-acting insulin analog lispro (LP) with that of regular insulin in IDDM patients treated with an external pump. RESEARCH DESIGN AND METHODS Thirty-nine IDDM patients (age, 39.4 ± 1.5 years; sex ratio, 22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dc6f060191d3c7513c8fc5d6c34bfb2
https://pubmed.ncbi.nlm.nih.gov/9614617
https://pubmed.ncbi.nlm.nih.gov/9614617
Autor:
Ravi Retnakaran, Helene Hanaire-Broutin, Bernard Zinman, J. Hans DeVries, V. Melki, Robert J. Heine
Publikováno v:
Diabetes Care. 28:1835-1836
With either continuous subcutaneous insulin infusion (CSII) or multiple daily insulin injection (MDII) therapy, the optimal meal insulin is a rapid-acting analog (lispro or aspart). To date, the efficacy of CSII versus MDII therapy has been evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51fcfc0fe5fb703e0a6403efe7458844
https://doi.org/10.2337/diacare.28.7.1835
https://doi.org/10.2337/diacare.28.7.1835
Autor:
Bruno Guerci, Eric Renard, J.-L. Selam, Nathalie Jeandidier, V. Lassman-Vague, L Rocher, Helene Hanaire-Broutin
Publikováno v:
Diabetes Care. 19:780-780
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d1b006bd343a3b1d9f6fbe6325476c0
https://doi.org/10.2337/diacare.19.7.780
https://doi.org/10.2337/diacare.19.7.780